A bluebird bio investigation has found a LentiGlobin gene therapy is “very unlikely” to have caused the acute myeloid leukemia (AML) that affected a recipient of a sickle cell treatment. Bluebird is now working with regulators to resume clinical trials in beta thalassemia and sickle cell disease.

As the lab instrument giant begins to lay down more roads into clinical testing—with recent diagnostics partnerships and cancer testing acquisitions—Agilent Technologies has also named its first chief medical officer to help guide the effort with the appointment of Katharine Knobil, M.D.

Takeda Pharmaceutical is advancing its immune-oncology portfolio with a lot of help from a Maverick – Maverick Therapeutics that is. The Japanese pharma giant announced today that it will acquire the immunotherapy pioneer it has been helping to build since its inception.

Deerfield Management has teamed up with medtech incubator Coridea to establish a new medical innovation firm in New York City.

Quench Bio’s short journey has come to an end after the biotech startup found that its target was simply undruggable.

Cognito Therapeutics has delivered clinical data from its digital treatment for patients with Alzheimer’s disease—which relies on light and sound to stimulate specific electrical frequencies in the brain’s neurons—showing it helped improve memory and cognition as well as physical symptoms.

FRAMINGHAM, Mass — Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced that Martin Tolar, MD, PhD, company’s Founder, President and Chief Executive Officer will present at the H.C. Wainwright Global Life Sciences Conference on March 9th. Presentation will be available live on-demand from 7:00 AM EST until the end of the conference on March 10th.

SEATTLE — NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the appointment of two new board members, Dr. Dana Rollison and Janet George, effective March 8, 2021.

Even with the promise of multiple vaccines and eventual reopenings, the COVID-19 pandemic has made the value of telehealth clear, and it’s here to stay. Now, Abbott is launching a virtual clinic that aims to put neuromodulation patients in touch with their physicians and have their treatments adjusted remotely.

TUCSON, Ariz. — Roche (SIX: RO, ROG; OTCQX:RHHBY) today announced US Food and Drug Administration (FDA) approval of the VENTANA ALK (D5F3) CDx Assay as a companion diagnostic to identify ALK-positive non-small cell lung cancer (NSCLC) patients eligible for treatment with Pfizer’s drug LORBRENA® (lorlatinib). The VENTANA ALK (D5F3) CDx Assay is the only immunohistochemistry (IHC) test approved by the FDA as a companion diagnostic for LORBRENA.